会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 9. 发明申请
    • COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS
    • 用于治疗病毒感染的组合物和方法
    • US20140356399A1
    • 2014-12-04
    • US14371935
    • 2013-01-11
    • Variation Biotechnologies, Inc.
    • David E. Anderson
    • A61K47/28C12N7/00A61K47/24A61K39/205A61K47/14
    • A61K47/28A61K39/12A61K39/205A61K39/39A61K47/14A61K47/24A61K2039/55555A61K2039/55566C12N7/00C12N2760/20134C12N2760/20171Y02A50/466
    • The present disclosure provides compositions and methods useful for treating viral infections. As described herein, the compositions and methods are based on the development of immunogenic compositions that include an inactivated virus in combination with a non-ionic surfactant vesicle (NISV). In certain embodiments at least a portion of the antigen present in the composition is physically associated with the NISV. In certain embodiments the compositions are lyophilized and subsequently rehydrated after a period of storage. In certain embodiments the rehydrated compositions exhibit greater potency as compared to otherwise equivalent compositions that lack the NISV. In certain embodiments the lyophilized compositions are stored at temperatures in excess of 8° C. prior to rehydration. In certain embodiments the rehydrated compositions exhibit greater potency as compared to otherwise equivalent compositions that lack the NISV and that were also stored at temperatures in excess of 8° C. prior to rehydration. In certain embodiments the antigen is taken from a licensed vaccine and the administered dose of antigen is less than the standard human dose for the licensed vaccine.
    • 本公开提供了可用于治疗病毒感染的组合物和方法。 如本文所述,组合物和方法基于包括与非离子表面活性剂囊泡(NISV)组合的灭活病毒的免疫原性组合物的开发。 在某些实施方案中,组合物中存在的至少一部分抗原与NISV物理相关。 在某些实施方案中,将组合物冻干并随后在储存一段时间后再水化。 在某些实施方案中,与缺乏NISV的其它等同组合物相比,再水化组合物表现出更大的效力。 在某些实施方案中,冻干组合物在再水化之前储存在超过8℃的温度下。 在某些实施方案中,与缺乏NISV的其它等同组合物相比,再水合组合物显示出更大的效力,并且在再水合之前也在超过8℃的温度下储存。 在某些实施方案中,抗原是从经许可的疫苗获得的,并且所给予的抗原剂量小于许可疫苗的标准人剂量。